Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia, today announced that it has drawn down a $4.1 million tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.
“These funds will enable us to complete the Phase 2 study for our lead anemia program, AKB-6548, and to continue the review process to select the right partner for our Phase 3 pivotal studies,” said Joseph Gardner, Ph.D., President and Chief Executive Officer of Akebia.
Separately today, Akebia Therapeutics announced that its Tie-2 activator (AKB-9778) and its HIF-1α stabilizer (AKB-4924) have been spun out to form a new stand-alone biotechnology company, Aerpio Therapeutics.
About AKB-6548 for Anemia
Akebia’s lead compound, AKB-6548, which is in Phase 2, is a potentially best-in-class hypoxia inducible factor – prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia. AKB-6548 offers many potential advantages, including an improved safety profile, oral once daily dosing and lower cost of goods, over traditional erythropoiesis stimulating agents (ESAs) currently used to treat anemia.
About Akebia Therapeutics
Akebia Therapeutics is a discovery and development company focused on the treatment of chronic anemia. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in Phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimulate endogenous EPO production. www.akebia.com
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Akebia/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
Singapore has always had a progressive healthcare system with prioritizing innovative solutions to the existing…
A Ponzi scheme is a fraudulent investment scheme that aims to give its investors high…
According to the Global Prop tech Survey, 2019 published by KPMG one of the key…
In April 2016, the world witnessed one of the biggest information leaks in history, consisting…
Silent Eight a global technology company that helps combat money laundering and terrorism financing using…
Indian startup Gully Network Retail Pvt Ltd, a retail-tech startup focused on providing services to…
Leave a Comment